Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female children who completed the previous four dose vaccination series study (NCT00129129). The age of the child at the 3 post-fourth dose timelines are as follows:~  * Year 1: 22 to 36 months of age.~ * Year 3: 44 to 60 months of age.~ * Year 5: 5 years post-dose 4 +/- 8 weeks~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study~* Having completed the fourth dose vaccination of study Hib-MenCY-TT-005/006~Exclusion Criteria:~Children should not have:~* received more than 4 doses of Hib or meningococcal serogroup C and Y vaccine~* had a history of H. influenzae type b, meningococcal serogroup C and Y diseases

- Gender: ALL
- Minimum Age: 22 Months
- Maximum Age: 60 Months
- Healthy Volunteers: t

Study Arms:
- MenHibrix 4-dose group (Type: EXPERIMENTAL): Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
- ActHIB 4-dose group (Type: ACTIVE_COMPARATOR): Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
- ActHIB 3-dose + MenHibrix 4th-dose group (Type: EXPERIMENTAL): Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.

Based on this trial design, predict the completion outcome and termination type (if applicable).